Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
Completed · Phase 1/Phase 2
Conditions studied: Melanoma, Ocular Melanoma, Uveal Melanoma
In brief
This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.
Key facts
- Study ID
- NCT04364230
- Run by
- Craig L Slingluff, Jr
- People needed
- 22
- Starts
- 2020-09-28
- Expected to finish
- 2024-03-14
- Last updated by the study team
- 2024-07-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
- University of Virginia — Charlottesville, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.